James R Hargreaves1, Anne Stangl2, Virginia Bond3, Graeme Hoddinott4, Shari Krishnaratne5, Hlengani Mathema4, Maureen Moyo6, Lario Viljoen4, Laura Brady2, Kirsty Sievwright2, Lyn Horn4, Kalpana Sabapathy7, Helen Ayles5,6, Nulda Beyers4, Peter Bock4, Sarah Fidler8, Sam Griffith9, Janet Seeley3, Richard Hayes7. 1. Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK james.hargreaves@lshtm.ac.uk. 2. International Center for Research on Women, 1120 20th St NW, Suite 500 North, Washington, DC 20036, USA. 3. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 4. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Lower Level Clinical Building, Fransie Van Zyl Street, Parow Valley, Cape Town, 7500, South Africa. 5. Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 6. Zambart, ZAMBART House, Ridgeway Campus, Lusaka, Zambia. 7. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 8. 7Department of Medicine, Imperial College London, London SW7 2AZ, UK. 9. FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA.
Abstract
BACKGROUND: Stigma and discrimination related to HIV and key populations at high risk of HIV have the potential to impede the implementation of effective HIV prevention and treatment programmes at scale. Studies measuring the impact of stigma on these programmes are rare. We are conducting an implementation science study of HIV-related stigma in communities and health settings within a large, pragmatic cluster-randomized trial of a universal testing and treatment intervention for HIV prevention in Zambia and South Africa and will assess how stigma affects, and is affected by, implementation of this intervention. METHODS/ DESIGN: A mixed-method evaluation will be nested within HIV prevention trials network (HPTN) 071/PopART (Clinical Trials registration number NCT01900977), a three-arm trial comparing universal door-to-door delivery of HIV testing and referral to prevention and treatment services, accompanied by either an immediate offer of anti-retroviral treatment to people living with HIV regardless of clinical status, or an offer of treatment in-line with national guidelines, with a standard-of-care control arm. The primary outcome of HPTN 071/PopART is HIV incidence measured among a cohort of 52 500 individuals in 21 study clusters. Our evaluation will include integrated quantitative and qualitative data collection and analysis in all trial sites. We will collect quantitative data on indicators of HIV-related stigma over 3 years from large probability samples of community members, health workers and people living with HIV. We will collect qualitative data, including in-depth interviews and observations from members of these same groups sampled purposively. In analysis, we will: (1) compare HIV-related stigma measures between study arms, (2) link data on stigma to measures of the success of implementation of the PopART intervention and (3) explore changes in the dominant drivers and manifestations of stigma in study communities and the health system. DISCUSSION: HIV-related stigma may impede the successful implementation of HIV prevention and treatment programmes. Using a novel study-design nested within a large, community randomized trial we will evaluate the extent to which HIV-related stigma affects and is affected by the implementation of a comprehensive combination HIV prevention intervention including a universal test and treatment approach.
RCT Entities:
BACKGROUND: Stigma and discrimination related to HIV and key populations at high risk of HIV have the potential to impede the implementation of effective HIV prevention and treatment programmes at scale. Studies measuring the impact of stigma on these programmes are rare. We are conducting an implementation science study of HIV-related stigma in communities and health settings within a large, pragmatic cluster-randomized trial of a universal testing and treatment intervention for HIV prevention in Zambia and South Africa and will assess how stigma affects, and is affected by, implementation of this intervention. METHODS/ DESIGN: A mixed-method evaluation will be nested within HIV prevention trials network (HPTN) 071/PopART (Clinical Trials registration number NCT01900977), a three-arm trial comparing universal door-to-door delivery of HIV testing and referral to prevention and treatment services, accompanied by either an immediate offer of anti-retroviral treatment to people living with HIV regardless of clinical status, or an offer of treatment in-line with national guidelines, with a standard-of-care control arm. The primary outcome of HPTN 071/PopART is HIV incidence measured among a cohort of 52 500 individuals in 21 study clusters. Our evaluation will include integrated quantitative and qualitative data collection and analysis in all trial sites. We will collect quantitative data on indicators of HIV-related stigma over 3 years from large probability samples of community members, health workers and people living with HIV. We will collect qualitative data, including in-depth interviews and observations from members of these same groups sampled purposively. In analysis, we will: (1) compare HIV-related stigma measures between study arms, (2) link data on stigma to measures of the success of implementation of the PopART intervention and (3) explore changes in the dominant drivers and manifestations of stigma in study communities and the health system. DISCUSSION: HIV-related stigma may impede the successful implementation of HIV prevention and treatment programmes. Using a novel study-design nested within a large, community randomized trial we will evaluate the extent to which HIV-related stigma affects and is affected by the implementation of a comprehensive combination HIV prevention intervention including a universal test and treatment approach.
Authors: Bulent Turan; Abigail M Hatcher; Sheri D Weiser; Mallory O Johnson; Whitney S Rice; Janet M Turan Journal: Am J Public Health Date: 2017-04-20 Impact factor: 9.308
Authors: Alan R Lifson; Sale Workneh; Abera Hailemichael; Richard F MacLehose; Keith J Horvath; Rose Hilk; Lindsey Fabian; Anne Sites; Tibebe Shenie Journal: HIV Clin Trials Date: 2018-04-24
Authors: James R Hargreaves; Triantafyllos Pliakas; Graeme Hoddinott; Tila Mainga; Constance Mubekapi-Musadaidzwa; Deborah Donnell; Ethan Wilson; Estelle Piwowar-Manning; Yaw Agyei; Nomtha F Bell-Mandla; Rory Dunbar; Ab Schaap; David Macleod; Sian Floyd; Peter Bock; Sarah Fidler; Janet Seeley; Anne Stangl; Virginia Bond; Helen Ayles; Richard J Hayes Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Shari Krishnaratne; Virginia Bond; Anne Stangl; Triantafyllos Pliakas; Hlengani Mathema; Pamela Lilleston; Graeme Hoddinott; Peter Bock; Helen Ayles; Sarah Fidler; James R Hargreaves Journal: AIDS Patient Care STDS Date: 2020-01 Impact factor: 5.078
Authors: Cecilia Akatukwasa; Monica Getahun; Alison M El Ayadi; Judith Namanya; Irene Maeri; Harriet Itiakorit; Lawrence Owino; Naomi Sanyu; Jane Kabami; Emmanuel Ssemmondo; Norton Sang; Dalsone Kwarisiima; Maya L Petersen; Edwin D Charlebois; Gabriel Chamie; Tamara D Clark; Craig R Cohen; Moses R Kamya; Elizabeth A Bukusi; Diane V Havlir; Carol S Camlin Journal: PLoS One Date: 2021-05-17 Impact factor: 3.752
Authors: Lario Viljoen; Tila Mainga; Rozanne Casper; Constance Mubekapi-Musadaidzwa; Dillon T Wademan; Virginia A Bond; Triantafyllos Pliakas; Chiti Bwalya; Anne Stangl; Mwelwa Phiri; Blia Yang; Kwame Shanaube; Peter Bock; Sarah Fidler; Richard Hayes; Helen Ayles; James R Hargreaves; Graeme Hoddinott; J Seeley; D Donnell; S Floyd; N Mandla; J Bwalya; K Sabapathy; S H Eshleman; D Macleod; A Moore; S H Vermund; K Hauck; K Shanaube Journal: Health Policy Plan Date: 2021-06-25 Impact factor: 3.344
Authors: Michael M Chanda; Amaya G Perez-Brumer; Katrina F Ortblad; Magdalene Mwale; Steven Chongo; Nyambe Kamungoma; Catherine Kanchele; Andrew Fullem; Leah Barresi; Till Bärnighausen; Catherine E Oldenburg Journal: AIDS Patient Care STDS Date: 2017-06-05 Impact factor: 5.078